Featured Publications

The recently-published SITC Combination Immunotherapy Task Force white paper, entitled “Combination immunotherapy: a road map” (Ott et al.), aims to identify the most promising prospects for combination therapy and address challenges associated with combinatorial approaches. Building on previous work on combination immunotherapy, this article is the first to address the use of mouse models, safety considerations in early clinical testing, the need for innovative early phase clinical trial designs, and appropriate safety and efficacy endpoints for early phase clinical trials, all in the specific setting of combination immunotherapy.

Guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma were also recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.​​​​​​​

Articles

CASE REPORT

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma the roleResponse after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of i...

Samuel Rosner, Filiz Sen and Michael Postow


CASE REPORT

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer case rLong-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic cas...

Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot and Karim Fizazi


COMMENTARY

SITC logoThe Why, what, and How of the New FACT standards for immune effector cells

Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States...

Marcela V. Maus and Sarah Nikiforow


MEETING REPORT

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting

As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...

Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton and Peter P. Yu

 

RESEARCH ARTICLE

Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues followingDifferential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis


RESEARCH ARTICLE

A systems biology approach to investigating the influence of exercise and fitness on the compositionA systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood

Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz


RESEARCH ARTICLE

Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell deathNano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death

We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...

Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge and Darrin Uecker


RESEARCH ARTICLE

Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors

Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (T...

Robert Aguilar, Justin M. Johnson, Patrick Barrett and Vincent K. Tuohy


RESEARCH ARTICLE

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in brDifferential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...

Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy


RESEARCH ARTICLE

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesPhase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...

Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma…

View all articles

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

JITC welcomes submissions to the following sections:

Society affiliation

Free Publication for Society Members

As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.

JITC Best Paper Awards

Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!

For more information please email info@sitcancer.org, call +1 414 271-2456, or visit http://sitcancer.org/journal.

SITC 2017

About SITC

The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.

Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

SITC Mission

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Advertisement

JITC logo

Advertisement